Institution identification

Institution ID

3331396

Institution full name and acronym

Bayer AG

ENCePP partner

No
Institution description
No information provided.
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Studies conducted by the institution

A Multinational Phase IV Study Evaluating “Real World” Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog alfa) for Routine Prophylaxis (TAURUS)
A Post-marketing Retrospective nOn-interventional study using naTionwide registries and electronic medical records to investigate the real-life Effectiveness and major bleeding Complications of oral anTicoagulants in Norwegian non-valvular Atrial Fibrillation patients (PROTECT-AF)
An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People with Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States
Comparative effectiveness of rivaroxaban and warfarin for stroke prevention in multi-morbid patients with nonvalvular atrial fibrillation
Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients (DAROL)
Evaluation of Clinical outcomes among non-valvular atrial fibrillatIon patients with renal dysfunction treated with warfarin or reduced dose rivaroxaban (CALLIPER)
FINE-REAL: Non-interventional study to collect real-world data and providing insights into the use of finerenone in routine clinical practice
Incidence and Trend of Ectopic Pregnancy 2009-2018 - A population-based Study
Observational Studies in Cancer Associated Thrombosis for Rivaroxaban – United Kingdom Cohort (OSCAR—UK)
Observational Study Evaluating Effectiveness and Safety of Real-World Treatment with Damoctocog alfa pegol in Previously Treated Patients with Hemophilia A (HEM-POWR)
Observational study evaluating long-term safety of real-world treatment with damoctocog alfa pegol in previously treated patients with hemophilia A (HA-SAFE)
OPTIMIS - Outcomes of HCC patients treated with TACE followed or not followed by sorafenib and the influence of timing to initiate sorafenib
PARABO - Pain evaluation in Radium-223 (Xofigo®) treated mCRPC patients with bone metastases – a non-interventional study in nuclear medicine centers
PrOspective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib (ON-TRK)
PRostAte Cancer vTe In SwEden: epidemiology and anticoagulation treatment of VTE (PRACTISE)
Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation (REASSURE)
Real World Outcomes of Patients Treated with Vericiguat in German Routine Care (ROVER)
Real-world comparative effectiveness of rivaroxaban versus heparin and phenprocoumon for the treatment and secondary prevention of venous thromboembolism (RECENT)
Real-world comparative effectiveness of stroke prevention in patients with atrial fibrillation treated with Factor Xa nonvitamin-K oral anticoagulants (NOACs) vs. Phenprocoumon (ReLoaDeD)
Real-world evidence for non-valvular atrial fibrillation patients treated with oral anticoagulation in the Nordics (REATTAIN)
RECORA- Regorafenib in patients with metastatic colorectal cancer (mCRC) after failure of standard therapy
REFINE: Regorafenib observational study in hepatocellular carcinoma
Risk association of orofacial cleft and glucocorticoids exposure during pregnancy: a meta-analysis (GC_OC)
Risk of anaphylactoid reactions of Iopromide after intra-arterial administration (UVIA Study)
RIVA-DM: Effectiveness and Safety of Rivaroxaban vs. Warfarin in Nonvalvular Atrial Fibrillation and Diabetes Mellitus: Analysis of Electronic Health Record Data
Safety profile of Ultravist in children and elderly (UV Age)
Study to Evaluate Physician Awareness and Knowledge of Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Monotherapies in Europe: an Observational Post-Authorisation Joint Safety Study (Safe-CAM)
Systematic Review and meta-analysis of PASS Studies Assessing the Effectiveness of Risk Minimisation Measures
URANIS –Data collection in urological centers during treatment with Ra-223 dichloride (Xofigo) within the framework of a non-interventional study assessing overall survival (OS) and effectiveness predictors of Ra-223 dichloride treated mCRPC patients in a real life setting in Germany
Xarelto Paediatric VTE PASS Drug Utilization Study: An observational, longitudinal, multi-source drug utilization safety study to evaluate the drug use patterns and safety of rivaroxaban oral suspension in children under two years with venous thromboembolism (XAPAEDUS)